Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sujatha Nallapareddy (NPI 1164578779)

Field	Value
Entity Type	Individual
Organization	Sujatha Nallapareddy
Address	1700 S Potomac St
City	Aurora
State	CO
ZIP	80012
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 26, 2007

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider’s commercial footprint is effectively Medicare-only: total Medicare revenue is $1.4M and there is no Medicaid billing on file, so the provider operates with a single-payer revenue base in the available data. The absence of Medicaid claims may reflect patient mix, referral patterns, or billing routed through another entity, and it constrains direct comparison across payers.

Revenue is highly concentrated in a small set of oncology drug codes: the precomputed top three Medicare codes account for 66.8% of total Medicare revenue, with J9271 contributing $593.4K (44.9% of Medicare revenue), J9264 contributing $165K (12.5%), and J1568 contributing $125.4K (9.5%). This concentration indicates the practice’s financial performance is tied heavily to reimbursed drug administration rather than a broad mix of outpatient services.

The code mix and volumes point to a hands-on oncology infusion practice focused on systemic cancer therapy and associated supportive care. High-revenue drug administrations such as J9271 (pembrolizumab), J9264 (paclitaxel protein-bound), and J1568 (IV immune globulin) combined with frequent chemotherapy administration codes like 96413 and infusion-related codes such as 96365 and G0498 signal ongoing in-office infusion services plus routine lab monitoring (85025, 80053, tumor markers).

Competitive standing is mixed across individual drugs: the provider is not a dominant national player overall, but shows above-typical presence on select agents — J9264 ranks #16 of 118 providers nationally (87th percentile) indicating a relatively strong position for paclitaxel protein-bound, while J9271 ranks #771 of 1841 (57th percentile) and J1568 ranks #143 of 381 (63th percentile), both characterized as typical or unremarkable national volume. These rank/percentile positions imply targeted strength in some chemotherapy lines rather than broad national dominance.

Operational throughput in office visits and chemotherapy administration is high relative to peers: 99214 (719 claims, $67.6K revenue) ranks in the 95th percentile and is labeled "notably above typical," and 96413 (590 claims, $61.4K revenue) ranks in the 94th percentile and is also labeled "notably above typical." In addition, add-on and continuation infusion code 96417 ranks in the 95th percentile, reinforcing evidence of substantial infusion volume and multi-drug administration sessions.

Claim counts underline scale in drug delivery and supportive agents: J9271 has 13.8K claims and J9264 has 16.5K claims, while J1568 has 3.8K claims, showing heavy claim-level activity for key oncology drugs. Supportive and ancillary therapies also appear regularly — for example, J0897 (denosumab) shows 3K claims and Q5122 (pegfilgrastim biosimilar) shows 348 claims — consistent with integrated cancer treatment plus bone health and growth factor support.

Tenure is long-standing: the provider’s NPI was enumerated on 2007-01-26 (~19 years ago), indicating nearly two decades of enrollment in the Medicare program and suggesting established referral relationships and operational continuity. Long tenure combined with concentrated oncology billing patterns supports the interpretation of an experienced, infusion-focused hematology/oncology practice.

The single-payer Medicare concentration introduces business risk and negotiating implications: with $1.4M in Medicare revenue and no Medicaid billing on file, the practice’s reimbursement exposure is concentrated in Medicare rates and drug reimbursements. That concentration may limit diversification of payer contracting leverage and makes revenue particularly sensitive to changes in Medicare drug payment policy or utilization of the high-revenue agents that drive 66.8% of Medicare revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

81 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,800	$40	$593.4K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	16,500	$10	$165K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,800	$30	$125.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	720	$90	$67.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$100	$61.4K
J0897	Injection, denosumab, 1 mg	3,000	$20	$54K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	350	$90	$31K
J1437	Injection, ferric derisomaltose, 10 mg	1,600	$20	$25.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	300	$80	$24.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	11,630	$1	$23.3K

Showing 1–10 of 81

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 81 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Sujatha Nallapareddy — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

81 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	10	40	10,700	$40	$520.5K
J9264	1	10	16,500	$10	$160.5K
J1568	8	30	2,240	$30	$101.5K
J0897	66	140	2,580	$20	$68.8K
J2506	5	10	370	$90	$32.3K
Q5122	3	10	320	$90	$30.7K
J0881	3	10	7,670	$1	$23.4K
J3490	17	60	50	$290	$23.1K
J1437	1	10	1,400	$20	$22.7K
96413	2	140	130	$100	$19.7K

Showing 1–10 of 81

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sujatha Nallapareddy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0
Manojkumar Bupathi	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Sujatha Nallapareddy, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Continuum Of Colorado	CO	Community/Behavioral Health Agency	$0	$61.3M
Developmental Pathways Inc	CO	Case Management Agency	$0	$37.2M
Hca Healthone LLC	CO	General Acute Care Hospital	$0	$24.4M
Ahiska Homecare LLC	CO	In Home Supportive Care Agency	$0	$22.3M
Beacon Home Care	CO	In Home Supportive Care Agency	$0	$22.1M
Developmental Pathways, Inc.	CO	Day Training/Habilitation Specialist	$0	$20.6M
Global Intersections, Inc.	CO	Developmentally Disabled Services Day Training Agency	$0	$19.7M
Bmh Corp.,llc	CO	In Home Supportive Care Agency	$0	$18.2M
Hero Dental Of Aurora PC	CO	Dentist	$0	$14M
Hans Adult Day Care LLC	CO	Adult Day Care Clinic/Center	$0	$13.2M

Sujatha Nallapareddy — Billing Profile & Reimbursement Data

Sign up for Sujatha Nallapareddy — Billing Profile & Reimbursement Data policy alerts

Sujatha Nallapareddy — Billing Profile & Reimbursement Data

Sign up for Sujatha Nallapareddy — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References